Aims: To evaluate the efficacy and safety of fasiglifam, an orally active G-protein-coupled receptor 40 agonist, in combination with the dipeptidyl peptidase-4 inhibitor sitagliptin, in patients with type 2 diabetes inadequately controlled with diet/exercise (AE metformin).
Fasiglifam (TAK-875) is an orally active G-protein-coupled receptor 40 (GPR40) agonist with a novel mechanism of action. GPR40 is a free fatty acid (FFA) transmembrane receptor that is expressed in pancreatic β cells, where it promotes glucose-dependent insulin secretion. [4] [5] [6] [7] Fasiglifam binds to the GPR40 receptor on β cells and activates Gα q11 , which initiates a signalling mechanism via the phospholipase C pathway, which ultimately stimulates insulin secretion. 7, 8 Findings from short-term, early-stage clinical trials show that fasiglifam improves glycaemic control and is well tolerated in healthy volunteers and patients with type 2 diabetes, including a low incidence of hypoglycaemia. [9] [10] [11] [12] [13] In a phase III trial conducted in Japan, a 24-week course of fasiglifam 25 or 50 mg once daily significantly reduced HbA1c levels compared with placebo (−0.59% and −0.84% , respectively; P < .0001) in patients with type 2 diabetes. Hypoglycaemia rates for fasiglifam 25 and 50 mg were similar to those for placebo. 14 In a 52-week, open-label, phase III study in Japan, the glycaemic control efficacy of fasiglifam 25 or 50 mg was sustained for up to 52 weeks, either as monotherapy or in combination with background single-agent antidiabetic therapy (either sulphonylurea, rapid-acting insulin secretagogue, α-glucosidase inhibitor, biguanide, thiazolidinedione, or dipeptidyl peptidase-4 inhibitor). 15 Sitagliptin is a highly selective orally active dipeptidyl peptidase-4
(DPP-4) inhibitor that delays glucagon-like peptide-1 (GLP-1) degradation and increases GLP-1 plasma concentrations. 16 GLP-1 promotes insulin secretion and decreases glucagon secretion in a glucose-dependent manner. 17 Sitagliptin alone and in combination with other antidiabetic agents improves HbA1c, fasting plasma glucose (FPG), postprandial glucose, and β-cell function in patients with type 2 diabetes. [18] [19] [20] [21] Because sitagliptin and fasiglifam stimulate insulin secretion via 2 different pathways, their effects on glycaemic control may be additive. To test this hypothesis, the effects of 2 doses of fasiglifam (25 and 50 mg) in combination with sitagliptin 100 mg on glycaemic control were assessed over 12 weeks in patients with type 2 diabetes who had not achieved adequate glycaemic control with diet and exercise, with or without metformin. In December 2013, after the present study had already been completed, the sponsor (Takeda) voluntarily terminated the development activities for fasiglifam because of concerns about liver safety. This decision was made after reviewing data from all phase III clinical studies of fasiglifam and consultation with expert committees overseeing the clinical programme. 22 2 | MATERIALS AND METHODS
| Patients and study design
This was a phase II, multicentre, randomized, placebo-controlled, to become pregnant were not eligible for enrolment. There were prespecified hyperglycaemic rescue criteria such that randomized patients who were rescued with additional antihyperglycaemic medication (metformin and/or glimepiride) continued in the study.
| Study endpoints and assessments
The primary endpoint was change in HbA1c from baseline to week symptomatic (hypoglycaemia symptoms with blood glucose levels of ≤3.9 mmol/L), asymptomatic (no symptoms but blood glucose levels of ≤3.9 mmol/L), probable symptomatic (symptoms but no blood glucose measurement), or relative (symptoms but blood glucose >3.9 mmol/L).
| Statistical analyses
A sample size of 360 patients (60 patients per group) was required to provide 80% power for detecting a difference of 0.5% in HbA1c
based on a pairwise comparison between one of the combination treatment groups and each of its respective component groups using a 2-sample t-test with a 2-sided significance level of 0.05. This was assuming a 0.9% common standard deviation for the change from baseline in HbA1c and a dropout rate of 15%.
All analyses included patients who were randomized and had ≥1 dose of study medication. Post-hyperglycaemic rescue data were excluded from efficacy endpoint analysis but included in safety summaries.
Change from baseline to week 12 in HbA1c (primary endpoint), Safety data were summarized using descriptive statistics. The incidence of hypoglycaemia was analysed using a logistic regression model with factors for treatment, baseline metformin use (yes/no), and baseline HbA1c category (<8.5% or ≥ 8.5%).
| RESULTS
The study was conducted between July 2011 and August 2012. Of 1153 patients screened, 368 were randomized to double-blind treatment, and 318 patients (86.4%) completed the study (Table S1 ). Reasons for premature discontinuation of treatment included withdrawal of consent (n = 16), AEs (n = 12), loss to follow-up (n = 11), major protocol deviation (n = 5), non-adherence (n = 4), sponsor request (n = 1), and lack of efficacy (n = 1). There were no meaningful differences across groups for the number of discontinuations resulting from AEs. The mean overall study drug adherence rate during double-blind treatment was >97% for each treatment group.
Demographic and baseline disease characteristics were generally similar across treatment groups (Table 1 ). Of the 368 randomized patients, 58.4% were men, 63.9% were obese (BMI ≥30 kg/m 2 ), 76.9% were using metformin at baseline, and 54.1% had a baseline HbA1c <8.5%. The mean age was 54.4 years, and the mean duration of type 2 diabetes was 7.4 years.
| Efficacy
Significantly greater reductions from baseline HbA1c were achieved by all active treatment groups in weeks 4 to 12 compared with placebo (P < .001). Both combination therapy regimens produced significantly greater HbA1c reductions compared with sitagliptin (P < .01)
or the respective doses of fasiglifam monotherapy (25 and 50 mg; P < .01) from baseline to week 12 ( Figure 1A and Table 2 ).
In all active treatment groups, FPG reductions occurred by week 1, with further reductions at week 2 that were sustained up to week 12 ( Figure 1B) . At week 12, FPG reductions for all active treatment groups were significantly greater than placebo (P < .001; Table 2 ).
Both combination therapy regimens resulted in significantly greater FPG reductions than sitagliptin alone (P < .01). Compared with fasiglifam 25 mg, the combination of fasiglifam 25 mg and sitagliptin resulted in significantly greater FPG reductions (P < .01), but differences between fasiglifam 50 mg and fasiglifam 50 mg plus sitagliptin combination therapy were not statistically significant (Table 2) . Significantly different changes from baseline in glucose AUC occurred for the active treatment groups vs placebo (P < .001) and for both combination regimens vs sitagliptin (P ≤ .001) and respective doses of fasiglifam 25 and 50 mg monotherapy (P < .01; Table 2 ).
Significantly greater reductions from baseline in patients' selfmonitored mean daily blood glucose concentrations were achieved by all drug-treated groups at week 4 and maintained up to week 12 compared with placebo (P < .001); reductions at week 12 were greater for both combination therapy regimens than for sitagliptin monotherapy (P < .001) or the respective dose of fasiglifam mono- Subgroup analyses showed that overall reductions in HbA1c
and FPG from baseline to week 12 were numerically greater in patients with higher baseline HbA1c (≥8.5%) than in those with lower baseline levels (<8.5%). For patients with baseline HbA1c Glucose AUC measured during 2-h OGTT at week 12.
Abbreviations: LS, least squares; NA, not applicable; s.e., standard error.
patients randomized to either combination therapy regimen or fasiglifam 25 or 50 mg.
There were no clinically meaningful changes from baseline in HOMA-IR, HOMA-β, fasting insulin, fasting C-peptide, or fasting glucagon at week 12 across treatment groups (Table S2) 
| Safety
The TEAEs reported by ≥5% of patients in any treatment group are summarized in Table 3 . Nausea, sinusitis, increased lipase, headache and hyperglycaemia were the most frequently reported. Most TEAEs were mild or moderate in intensity (≥89% across treatment groups). If a patient had >1 TEAE with the same preferred term, the patient was counted only once for that preferred term.
2 diabetes who are treated with oral agents, higher baseline HbA1c levels (≥8.0%) correlate with greater improvements in HbA1c and This is consistent with results from other studies of fasiglifam and sitagliptin. [9] [10] [11] [12] [13] 19, 24 and was not surprising, given that both agents stimulate insulin release in a glucose-dependent manner.
The incidence of elevated liver enzymes (>3 times the ULN) in patients who received fasiglifam alone or in combination with sitagliptin was higher than the incidence in the placebo or sitagliptin monotherapy groups, although there were no patients with elevated liver enzymes accompanied by signs of loss of liver function. Nonetheless, based on a subsequent review of all phase III data, the clinical development of fasiglifam was discontinued because of concerns over liver safety, and a series of in vivo and in vitro experiments were performed to identify mechanisms underlying potential adverse hepatic effects. 27 Results from these studies suggest that inhibition of hepatobiliary transport by fasiglifam may be involved in the mechanism of hepatotoxicity.
Possible study limitations include the relatively short duration of treatment, which may be insufficient to evaluate the sustained effect of fasiglifam plus sitagliptin on glycaemic control and tolerability; therefore, larger and longer clinical studies would have been needed to confirm the findings from this phase II study if the fasiglifam programme had not been terminated.
In conclusion, the combination of the GPR40 agonist fasiglifam with the DPP-4 inhibitor sitagliptin demonstrated a significant additional effect on glycaemic efficacy with hypoglycaemia rates similar to those of placebo. Fasiglifam alone or in combination with sitagliptin appeared to be well tolerated and weight-neutral in this 12-week, phase II study, but with a higher incidence of liver transaminase elevations in fasiglifam-treated patients. Although the clinical development of the GPR40 agonist fasiglifam has been discontinued as a result of concerns about hepatic safety, targeting GPR40 remains a viable and highly promising option for the treatment of type 2 diabetes. 26 The present study is the only trial, to our knowledge, to provide clinical evidence supporting the hypothesis of potential complementary mechanisms of action between GPR40 agonists and DPP-4 inhibitors, which could provide some value for potential future development of other GPR40 agonists for treatment of type 2 diabetes.
